论文部分内容阅读
目的：观察玻璃体腔注射雷珠单抗联合 Ahmed引流阀植入治疗新生血管性青光眼（NVG）的疗效。方法 NVG患者28例分为两组：A组9例，先行玻璃体腔注射雷珠单抗0.5 mg ，待虹膜新生血管消退后行Ahmed引流阀植入术；B组19例，仅行Ahmed引流阀植入术。比较两组患者术中、术后前房出血及眼压变化。结果两组术后第1、7天眼压均低于术前（P＜0．05），A组眼压均低于B组（P＜0．05）。A组患者用药3‐4 d后虹膜新生血管大部分消退，术后1例见前房少量血凝块；B组术中、术后前房出血。结论玻璃体腔注射雷珠单抗联合Ahmed阀植入治疗 NVG安全有效，并发症少。“,”Objective To observe the efficacy of intravitreal ranibizumab injection combined with Ahmed valve implantation in the treatment of neovascular glaucoma(NVG) .Methods Twenty‐eight NVG patients were divided into two groups .The patients in group A(9 cases) were treated with intravitreal ranibizumab injection 0.5 mg combined with Ahmed valve implantation and those in group B(19 cases) were treated with Ahmed valve implantation .Anterior chamber bleeding and intraocular pressure(IOP) changes were compared between two group .Results On the 1st and 7th postoperative day ,IOP was lower than that before in both groups(P<0 .05) ,which was lower in group A than that in group B(P<0 .05) .The majority of the iris neovassels in group A were disappeared within 3 to 4 days after intravitreal ranibizumab injection .Hyphema was observed in one case in group A and in 13 cases in group B after Ahmed valve implantation .Conclusion Intravitreal ranibizumab injection combined with Ahmed valve implantation is effective and safe in the treatment of NVG whith less complications .